伯乐生命医学

最新新闻

• 评级变动
  Clear Street Initiates Q32 Bio(QTTB.US) With Buy Rating, Announces Target Price $38
  \u5e02\u573a\u8d44\u8baf · 2026/9/29
• 评级变动
  Wedbush Maintains Adicet Bio(ACET.US) With Buy Rating, Raises Target Price to $28
  \u5e02\u573a\u8d44\u8baf · 2026/9/29
• H.C. Wainwright Maintains Kyntra Bio(KYNB.US) With Buy Rating, Maintains Target Price $43
  \u5e02\u573a\u8d44\u8baf · 2026/10/5
• RBC Capital Maintains Bio-Rad Laboratories(BIO.US) With Buy Rating, Maintains Target Price $390
  \u5e02\u573a\u8d44\u8baf · 2026/9/28
• 评级变动
  CCORF Maintains Adicet Bio(ACET.US) With Buy Rating, Maintains Target Price $18
  \u5e02\u573a\u8d44\u8baf · 2026/9/29
• 评级变动
  H.C. Wainwright Maintains Q32 Bio(QTTB.US) With Buy Rating, Maintains Target Price $36
  \u5e02\u573a\u8d44\u8baf · 2026/10/1
• 评级变动
  Lake Street Maintains TELA Bio(TELA.US) With Buy Rating, Maintains Target Price $2
  \u5e02\u573a\u8d44\u8baf · 2026/9/30
• 评级变动
  Stifel Maintains Braveheart Bio(BRVE.US) With Buy Rating, Maintains Target Price $45
  \u5e02\u573a\u8d44\u8baf · 2026/10/1
• 公司公告
  Huaheng Bio: Implementation and Assessment Management Measures for the 2026 Restricted Stock Incentive Plan of Anhui Huaheng Biotechnology Co., Ltd.
  SZSI · 2026/9/30
• Citi Maintains Nuvation Bio(NUVB.US) With Buy Rating, Maintains Target Price $12
  \u5e02\u573a\u8d44\u8baf · 2026/10/2
• 评级变动
  Clear Street Maintains Q32 Bio(QTTB.US) With Buy Rating, Maintains Target Price $38
  \u5e02\u573a\u8d44\u8baf · 2026/10/1
• 评级变动
  Citi Initiates Nuvation Bio(NUVB.US) With Buy Rating, Announces Target Price $12
  \u5e02\u573a\u8d44\u8baf · 2026/9/30
• 公司公告
  Climb Bio | 4: Statement of changes in beneficial ownership of securities-Director RA CAPITAL MANAGEMENT, L.P.
  SEC · 2026/10/1
• 公司公告
  Shengda Bio: Announcement on the Establishment of a Dedicated Settlement Account for Cash Management of Raised Funds and Progress in Utilizing Idle Raised Funds for Cash Management by Zhejiang Shengda Bio‑Pharmaceutical Co., Ltd.
  SZSI · 2026/10/1
• 公司公告
  Chengda Bio: Materials for the Second Extraordinary Shareholders' Meeting of Liaoning Chengda Bio Co., Ltd. for 2026
  SZSI · 2026/10/1
• 公司公告
  L&C BIO Co: Report on Status of Specific Securities, Etc. Owned by Executives and Major Shareholders
  OPENDART · 2026/9/30
• Wells Fargo Maintains Q32 Bio(QTTB.US) With Buy Rating, Maintains Target Price $59
  \u5e02\u573a\u8d44\u8baf · 2026/10/1
• Jefferies Maintains Q32 Bio(QTTB.US) With Buy Rating, Maintains Target Price $29
  \u5e02\u573a\u8d44\u8baf · 2026/10/1
• 评级变动
  H.C. Wainwright Maintains Adicet Bio(ACET.US) With Buy Rating, Maintains Target Price $34
  \u5e02\u573a\u8d44\u8baf · 2026/9/30
• 评级变动
  BTIG Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $32
  \u5e02\u573a\u8d44\u8baf · 2026/10/2

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。